All updated as on -
With a CAGR of 10.4% between 2023 and 2030, the global blood plasma derivatives market is expected to grow from its 2020 valuation of $36,471.9 mln to reach $89,769 mln. Plasma is a protein salt solution that makes up the clear, straw-colored liquid component of blood. Blood plasma contains three types of cells: red blood cells, white blood cells, and platelets. Albumin, fibrinogen, immunoglobulin, protease inhibitors, and clotting factor are just a few of the more than a hundred proteins found in plasma. It's crucial in regulating blood pressure and facilitating the exchange of minerals like salt and potassium.
As you likely already know, platelets and the protein responsible for blood clotting are found in plasma, the liquid component of blood. Fractionation of purified plasma proteins yields plasma derivatives. Dissolvable cleansers that have been chemically or thermally modified to kill off specific pathogens make up the Derivatives. Factor IX concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, factor VIII concentrate, Alpha 1-Proteinase inhibitor concentrate, insensitive globulins, egg whites, and anti-thrombin III concentrates make up the bulk of the most well-known plasma derivatives. Clinical use of blood plasma derivatives 3 is widespread, and includes the treatment of a wide variety of diseases and disorders.
The market for blood plasma derivatives is growing due to the increasing need for plasma-based therapies. A 2016 study published in the Journal of Plasma Medicine found that FIX substitution therapy, which makes use of plasma-inferred protein, is effective in reducing haemophilia B-related disability and exhaustion. The most frequent bleeding disorders in the Middle East and Africa are haemophilia and von Willebrand disease (VWD). Due of plasma's efficacy in medicine, demand for blood plasma derivatives has been rising as of late.
One of the primary factors boosting the market for blood plasma derivatives is the occurrence of serious diseases including haemophilia and immune deficiency disorders. The widespread use of blood plasma derivative products and the growing elderly population are also fueling the market's expansion. The report, titled "Global Blood Plasma Derivatives Market," offers a comprehensive analysis of the business. The research provides a thorough examination of the market's most important subsegments, trends, drivers, restraints, competitive landscape, and other variables.
The blood cells float in the plasma, the liquid component of blood. Proteins (albumins, globulins, and fibrinogen) are dissolved in the fluid and work together with hormones and electrolytes to regulate blood coagulation. Plasma helps maintain a steady blood pressure and aids in the exchange of electrolytes like salt and potassium to maintain a healthy internal pH. Plasma derivatives are manufactured goods derived from human plasma using plasma fractionation processes. Some examples of these modifications include albumin, factor VIII and IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins such Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.
Growing incidences of haemophilia and improvements in health-related issues due to societal shifts are driving the global blood plasma derivatives market. Additionally, increasing demand for healthcare and the prevalence of immunodeficiency diseases are expected to propel the market forward. Increased government incentives for collecting plasma and improving awareness among consumers are also contributing to the market's expansion. The pie is predicted to grow as a result of several factors, including a greater focus on innovation, the expansion of medical service regions, the growing rate of the elderly population, and the growing acceptance of plasma-derived products. The rising number of advocates for blood plasma derivatives is a key factor propelling the industry forward. As the worldwide market expands, more and more clinical trials will be conducted to determine the safety and effectiveness of various therapeutic drugs.
The growing prevalence of thrombocytosis is one factor fueling the expansion of the blood plasma derivatives industry worldwide. Mindfulness programmes for preventing thrombocytosis and its complications are run by the National Institutes of Health (NIH) and the Centres for Disease Control and Prevention (CDC). The predicted value of the global blood plasma derivatives market for the years 2017–2023 is US$ 30.5 billion, with a compound annual growth rate (CAGR) of 7.52%. The market for blood plasma derivatives is expected to expand because of this factor. The predicted growth of the plasma products and derivatives market is likely to be hampered by a post-usable risk associated with treatment of plasma derivatives.
Report Coverage
Global Blood Plasma Derivatives research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Blood Plasma Derivatives report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Blood Plasma Derivatives competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Blood Plasma Derivatives market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Blood Plasma Derivatives market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Blood Plasma Derivatives market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, Fusion Healthcare, SK Plasma Co., Ltd., Biotest AG, Green Cross Corporation, and Shire Plc.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Blood Plasma Derivatives market based on the below-mentioned segments:
Global Blood Plasma Derivatives Market, By Type
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others
Global Blood Plasma Derivatives market, By Application
Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand'S Disease
Other Application
Global Blood Plasma Derivatives Market, By End User
Hospitals
Clinics
Other End Users
Global Blood Plasma Derivatives market, Regional Analysis
As you likely already know, platelets and the protein responsible for blood clotting are found in plasma, the liquid component of blood. Fractionation of purified plasma proteins yields plasma derivatives. Dissolvable cleansers that have been chemically or thermally modified to kill off specific pathogens make up the Derivatives. Factor IX concentrate, anti-inhibitor coagulation complex (AICC), anti-thrombin III concentrate, factor VIII concentrate, Alpha 1-Proteinase inhibitor concentrate, insensitive globulins, egg whites, and anti-thrombin III concentrates make up the bulk of the most well-known plasma derivatives. Clinical use of blood plasma derivatives 3 is widespread, and includes the treatment of a wide variety of diseases and disorders.
The market for blood plasma derivatives is growing due to the increasing need for plasma-based therapies. A 2016 study published in the Journal of Plasma Medicine found that FIX substitution therapy, which makes use of plasma-inferred protein, is effective in reducing haemophilia B-related disability and exhaustion. The most frequent bleeding disorders in the Middle East and Africa are haemophilia and von Willebrand disease (VWD). Due of plasma's efficacy in medicine, demand for blood plasma derivatives has been rising as of late.
One of the primary factors boosting the market for blood plasma derivatives is the occurrence of serious diseases including haemophilia and immune deficiency disorders. The widespread use of blood plasma derivative products and the growing elderly population are also fueling the market's expansion. The report, titled "Global Blood Plasma Derivatives Market," offers a comprehensive analysis of the business. The research provides a thorough examination of the market's most important subsegments, trends, drivers, restraints, competitive landscape, and other variables.
The blood cells float in the plasma, the liquid component of blood. Proteins (albumins, globulins, and fibrinogen) are dissolved in the fluid and work together with hormones and electrolytes to regulate blood coagulation. Plasma helps maintain a steady blood pressure and aids in the exchange of electrolytes like salt and potassium to maintain a healthy internal pH. Plasma derivatives are manufactured goods derived from human plasma using plasma fractionation processes. Some examples of these modifications include albumin, factor VIII and IX, anti-inhibitor coagulation complex (AICC), and immunoglobulins such Rh immune globulin, alpha 1-proteinase inhibitor concentrate, and anti-thrombin III.
Growing incidences of haemophilia and improvements in health-related issues due to societal shifts are driving the global blood plasma derivatives market. Additionally, increasing demand for healthcare and the prevalence of immunodeficiency diseases are expected to propel the market forward. Increased government incentives for collecting plasma and improving awareness among consumers are also contributing to the market's expansion. The pie is predicted to grow as a result of several factors, including a greater focus on innovation, the expansion of medical service regions, the growing rate of the elderly population, and the growing acceptance of plasma-derived products. The rising number of advocates for blood plasma derivatives is a key factor propelling the industry forward. As the worldwide market expands, more and more clinical trials will be conducted to determine the safety and effectiveness of various therapeutic drugs.
The growing prevalence of thrombocytosis is one factor fueling the expansion of the blood plasma derivatives industry worldwide. Mindfulness programmes for preventing thrombocytosis and its complications are run by the National Institutes of Health (NIH) and the Centres for Disease Control and Prevention (CDC). The predicted value of the global blood plasma derivatives market for the years 2017–2023 is US$ 30.5 billion, with a compound annual growth rate (CAGR) of 7.52%. The market for blood plasma derivatives is expected to expand because of this factor. The predicted growth of the plasma products and derivatives market is likely to be hampered by a post-usable risk associated with treatment of plasma derivatives.
Report Coverage
Global Blood Plasma Derivatives research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Blood Plasma Derivatives report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Blood Plasma Derivatives competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Blood Plasma Derivatives market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2022 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2021 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, Fusion Healthcare, SK Plasma Co., Ltd., Biotest AG, Green Cross Corporation, and Shire Plc. |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Blood Plasma Derivatives Market from 2021 to 2030.
- Market Forecast for Blood Plasma Derivatives Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Blood Plasma Derivatives competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Blood Plasma Derivatives
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Blood Plasma Derivatives market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Blood Plasma Derivatives market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, Fusion Healthcare, SK Plasma Co., Ltd., Biotest AG, Green Cross Corporation, and Shire Plc.
Primary Target Market
- Market Players of Blood Plasma Derivatives
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. INFINITIVE DATA EXPERT has segmented the global Blood Plasma Derivatives market based on the below-mentioned segments:
Global Blood Plasma Derivatives Market, By Type
Albumin
Factor VIII
Factor IX
Immunoglobulin
Hyperimmune Globulin
Others
Global Blood Plasma Derivatives market, By Application
Hemophilia
Hypogammaglobulinemia
Immunodeficiency Diseases
Von Willebrand'S Disease
Other Application
Global Blood Plasma Derivatives Market, By End User
Hospitals
Clinics
Other End Users
Global Blood Plasma Derivatives market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive blood plasma derivatives market market research and competitor analysis for your business to help you develop more profound insights into the blood plasma derivatives market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the blood plasma derivatives market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.